Enigma announces commencement of ML system evaluation at Guy’s and St Thomas’ NHS Foundation Trust

Salisbury, England, 14th December 2012 – Enigma Diagnostics Ltd announces that it is to carry out pre-clinical diagnostic verification of its FluAB-RSV diagnostic assay on the Enigma® ML system at Guy’s and St Thomas’ NHS Foundation Trust.

Enigma has installed a number of ML instruments at Guy’s and St Thomas’ and will provide FluAB-RSV test cartridges for use at the Trust’s Centre for Clinical Infection and Diagnostics Research (CIDR).
The Enigma® ML system has the capability to deliver PCR-based results from a raw sample in 60 minutes and Enigma, in addition to the FluAB-RSV test scheduled for CE marking in mid-2013, is developing a series of deeply multiplexed assays for the ML including panel tests for respiratory viruses, MDR-TB and sexual health infections.
John McKinley, Chairman of Enigma Diagnostics, said: “We are delighted to be collaborating with such a prestigious and influential clinical centre. Our ongoing relationship with Guy’s and St Thomas’ NHS Foundation Trust has already proven invaluable in defining the clinical requirements of the ML system. Enigma’s core mission is to provide easy to use and cost effective molecular diagnostics at the point of need.”
Dr Jonathan Edgeworth, Consultant Microbiologist and Head of the Centre for Clinical Infection and Diagnostics Research said: “We are pleased that Enigma has chosen Guy’s and St Thomas’ as its partner to test the performance of the ML system. This will provide an opportunity to influence the development of a testing system that has potential to benefit patients in the future.

SEARCH Press Releases :